证券代码：838810 证券简称：春光药装 公告编号：2023-020 辽宁春光制药装备股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2023 年 4 月 22 日 2.会议召开地点：公司会议室 3.会议召开方式：现场及通讯方式 4.发出董事会会议通知的时间和方式：2023 年 4 月 12 日以书面方式发出 5.会议主持人：毕春光 6.会议列席人员：监事及高级管理人员 7.召开情况合法、合规、合章程性说明： 第三届董事会第十九次会议决议公告 本次会议的召集、召开符合《公司法》《公司章程》《董事会议事规则》的相 关规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 董事张丽因工作原因以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于 2022 年度董事会工作报告的议案》 1.议案内容： 由董事长汇报公司 2022 年度董事会工作报告情况，对执行董事会决议和股 东大会决议方面进行了全面总结 ...

辽宁春光制药装备股份有限公司 募集资金存放与使用情况鉴证报告 大华核字[2023]000486 号 大华会计师事务所(特殊普通合伙) Da Hua Certified Public Accountants (Special General Partnership) 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn） and and company of the company of the company of the company of the company of the company of the company of the company of the company of the compare of the consection of (2022年 ) | 1-2 | | | --- | --- | | " | 1-6 | (10) 5835 0011 传真: 86 (10) 5 募 集 资 金 存 放 与 使 用 情 况 鉴 证 报 告 大华核字[2023]000486 号 辽宁春光制药装备股份有限公司全体股东: 我们审核了后附的辽宁春光 ...

春光药装控股股东、实际控制人不存在接受他人表决权委托的情况，控股股东所持 股份不存在冻结、质押等情况，控股子公司不存在持有上市公司股份的情形。 中信建投证券股份有限公司 关于辽宁春光制药装备股份有限公司 开展公司治理专项自查及规范活动的专项核查报告 中信建投证券股份有限公司（以下简称"中信建投"或"保荐机构"）作为辽宁春 光制药装备股份有限公司（以下简称"春光药装"或"上市公司"）股票向不特定合格 投资者公开发行的保荐机构，根据《证券发行上市保荐业务管理办法》《北京证券交易 所证券发行上市保荐业务管理细则》《北京证券交易所股票上市规则（试行）》（以下 简称"《上市规则》"）《关于开展挂牌公司治理专项自查及规范活动的通知》等有关 规定要求，对春光药装 2022 年度公司治理等情况进行了核查，具体情况如下： 一、 上市公司情况 春光药装股票于 2022 年 12月 16日在北京证券交易所上市。依据证监会行业分类， 所属行业为"C35 专用设备制造"，主营业务为药品及食品包装装备的研发、生产和销 售。 截至 2022 年末，春光药装控股股东、实际控制人为毕春光、边境。毕春光直接持 有上市公司 26.67%股份，通过 ...

证券代码：838810 证券简称：春光药装 公告编号：2023-022 辽宁春光制药装备股份有限公司 独立董事关于第三届董事会第十九次会议 相关事项的事前认可意见及独立意见 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 根据有关法律、法规、监管要求、《公司章程》《独立董事制度》等相关规定， 作为辽宁春光制药装备股份有限公司（以下简称"公司"）独立董事，现就第三届 董事会第十九次会议相关事项发表事前认可意见及独立意见如下： 一、《关于公司预计 2023 年日常性关联交易的议案》的事前认可意见 经认真审阅议案的相关材料，我们认为：本次公司预计 2023 年日常性关联 交易事项符合公司实际经营发展的需要，有利于公司生产经营持续健康进行，对 公司财务状况、经营成果及独立性带来积极的作用，能够帮助公司经营平稳发展。 不存在违反相关法律法规的情形，不存在损害公司及全体股东特别是中小股东利 益的情形。 因此，我们同意将《关于公司预计 2023 年日常性关联交易的议案》提交公 司第三届董事会第十九次会议审议。 二、《 ...

辽宁春光制药装备股份有限公司 控股股东及其他关联方资金占用情况的 专项说明 大华核字[2023]000485 号 大华会计师事务所(特殊普通合伙) DaHua Certified Public Accountants (Special General Partnership ) 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.nof.gov.cn）" (截 22年 12月 31日 ) 女公母都被授。 出生味曾通合伙 京市海淀区西四环中路 16 号院 7 号楼 12 层 [10 电话: 86 (10) 5835 0011 传真: 86 (10) 5835 0006 控 股 股 东 及 其 他 关 联 方 资 金 占 用 情 况 的 专 项 说 明 大华核字[2023]000485 号 辽宁春光制药装备股份有限公司全体股东: 我们接受委托,依据《中国注册会计师执业准则》审计了辽宁春 光制药装备股份有限公司(以下简称辽宁春光公司)2022 年度财务 报表,包括 2022年12月 31日的合并及母公司资产负债表,2022年 度的合并及母公司利润表、合并及母公司现金流量表和合并及母公司 ...

二、审议与表决情况 2023 年 4 月 22 日，公司召开第三届董事会第十九次会议，审议通过了《关 于公司全资子公司向中国建设银行申请授信暨公司为全资子公司提供担保的议 案》，表决情况：同意 9 票，反对 0 票，弃权 0 票。回避表决情况：议案不涉及 关联交易，无需回避表决。议案尚需提交 2022 年年度股东大会审议。 三、资产抵押的必要性 证券代码：838810 证券简称：春光药装 公告编号：2023-032 辽宁春光制药装备股份有限公司 全资子公司资产抵押公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、基本情况 根据公司战略发展需求，辽宁春光制药装备股份有限公司（以下简称"公司"） 全资子公司辽宁典冠科技有限公司（以下简称"典冠科技"）拟向中国建设银行 股份有限公司锦州分行申请授信，授信有效期为 8 年，授信金额为 1.6 亿元，公 司为典冠科技提供担保，公司实际控制人、控股股东毕春光、边境以个人信用为 典冠科技提供个人连带责任保证，典冠科技项目土地及厂房作为该授信的抵押物 （具备抵押 ...

Financial Performance - Operating revenue for the first quarter of 2023 was CNY 51,045,814.36, representing a year-on-year growth of 27.85%[10] - Net profit attributable to shareholders for the first quarter of 2023 was CNY 7,684,095.67, up 33.17% from the same period last year[10] - The net profit margin for the first quarter of 2023 was approximately 15.08%, reflecting improved profitability[10] - Total operating revenue for Q1 2023 reached ¥51,045,814.36, a significant increase from ¥39,927,026.95 in Q1 2022, representing a growth of approximately 28.1%[54] - Net profit for Q1 2023 was ¥7,684,095.67, up from ¥5,770,196.79 in Q1 2022, reflecting a growth of approximately 33.3%[56] - The total comprehensive income amounted to 7,982,611.80, compared to 5,770,196.79 in the previous year[60] Assets and Liabilities - Total assets as of March 31, 2023, reached CNY 442,797,535.41, an increase of 2.03% compared to the end of 2022[10] - Total liabilities amounted to CNY 153,059,579.47, slightly up from CNY 152,040,697.45, reflecting a marginal increase of 0.67%[48] - Shareholders' equity reached CNY 289,737,955.94, compared to CNY 281,951,875.27, marking an increase of approximately 2.78%[48] - Current assets totaled CNY 357,241,080.85, an increase from CNY 347,271,541.50, reflecting a growth of about 2.83%[46] - Total assets at the end of the reporting period were ¥412,018,697.07, up from ¥403,055,478.26, reflecting a growth of about 2.4%[52] Cash Flow - The net cash flow from operating activities decreased by 128.79% to CNY -2,818,387.26 compared to the previous year[11] - Cash inflow from operating activities was 41,317,783.97, down from 45,804,214.16 in the same period last year, representing a decrease of approximately 9.7%[61] - Total cash outflow from operating activities was 44,136,171.23, compared to 36,013,677.83 in the previous year, indicating an increase of about 22.6%[63] - Cash and cash equivalents decreased to CNY 152,264,619.45 from CNY 178,406,927.66, a decline of approximately 14.65%[46] Expenses - Research and development expenses for the first quarter of 2023 amounted to CNY 136,420.00, a decrease of 35.48% year-on-year[14] - Sales expenses increased by 187.72% to CNY 4,516,200.00 due to increased marketing activities[14] - Total operating costs for Q1 2023 were ¥42,403,116.82, compared to ¥33,655,772.00 in Q1 2022, indicating an increase of about 26.0%[55] - Research and development expenses for Q1 2023 were ¥1,364,229.54, down from ¥2,114,302.53 in Q1 2022, indicating a reduction of approximately 35.3%[55] Shareholder Information - The total number of unrestricted shares decreased from 22,753,221 to 22,691,646, representing a change of -61,575 shares, which is a decrease of approximately 0.27%[22] - The total number of restricted shares increased from 45,746,779 to 45,808,354, representing a change of 61,575 shares, which is an increase of approximately 0.13%[22] - The largest shareholder, Bi Chunguang, holds 18,301,266 shares, accounting for 26.72% of the total shares[25] - The second largest shareholder, Bianjing, holds 13,596,309 shares, accounting for 19.85% of the total shares[25] - The top ten shareholders collectively hold 47,663,280 shares, which is 69.60% of the total shares[25] Commitments and Guarantees - The company has provided guarantees totaling 27,900,000 CNY for loans, with a remaining guarantee balance of 26,900,000 CNY[31] - The company applied for a loan of 9 million CNY from China Everbright Bank, with a guarantee provided by a related party[32] - The company applied for a loan of 5 million CNY from CITIC Bank, with a guarantee provided by the actual controller[32] - The actual controller has committed to not occupying company funds since February 2016, and this commitment is currently being fulfilled[34] - The company has established internal control measures to prevent fund occupation or asset transfer by shareholders and related parties[36] Compliance and Regulatory Matters - The company guarantees that its issuance application documents do not contain false records or misleading statements, and will initiate a share buyback if such issues are identified[39] - The company will disclose specific reasons for any failure to fulfill commitments in a timely manner[39] - The company will ensure compliance with relevant laws and regulations in handling any non-fulfillment of commitments[39] - The company will publicly disclose reasons for any failure to fulfill commitments and apologize to shareholders and the public[38]

Financial Performance - The company achieved a revenue of 216.08 million yuan in 2022, representing a year-on-year increase of 21.6% compared to 2021[14]. - The company's operating revenue for 2022 was ¥216,082,516.98, representing a year-over-year increase of 21.02% compared to ¥178,544,464.08 in 2021[31]. - Net profit reached 41.01 million yuan, reflecting a year-on-year growth of 17.33%[53]. - The net profit attributable to shareholders for 2022 was ¥41,013,230.25, which is a 17.33% increase from ¥34,956,681.11 in 2021[31]. - The total assets at the end of 2022 reached ¥433,992,572.72, marking an 80.96% increase from ¥239,830,757.53 at the end of 2021[33]. - The company's net assets attributable to shareholders increased by 190.37% to ¥281,951,875.27 in 2022 from ¥97,102,408.23 in 2021[33]. - The gross profit margin for 2022 was 47.13%, down from 50.72% in 2021[31]. - The cash flow from operating activities for 2022 was ¥48,321,113.32, a decrease of 9.74% from ¥53,538,177.03 in 2021[35]. - The company's cash and cash equivalents increased to ¥178.41 million, a growth of 747.60% compared to ¥21.05 million in the previous year, primarily due to funds raised from a public offering of shares[63]. Accounts Receivable and Risks - The accounts receivable for 2022 amounted to 91.89 million yuan, which is an increase from 49.66 million yuan in 2021, indicating a rising trend in credit sales[14]. - The company reported a significant increase in accounts receivable as a percentage of revenue, rising from 27.81% in 2021 to 42.52% in 2022, indicating potential cash flow risks[14]. - Accounts receivable rose to ¥58.56 million, reflecting a 134.34% increase from ¥24.99 million, attributed to slower payment collection from downstream food and pharmaceutical enterprises[63]. - The company faces risks related to technological innovation, including potential project failures and market acceptance issues[13]. - The company has implemented appropriate internal controls related to accounts receivable impairment, ensuring accurate financial reporting[119]. Corporate Structure and Governance - The company maintains a concentrated ownership structure, with the actual controllers holding 46.48% of the shares, which may impact corporate governance and decision-making[15]. - The actual controller of the company is Bi Chunguang, with significant shareholders including Bianjing[25]. - The company has established a wholly-owned subsidiary, Liaoning Dianguan Technology Co., Ltd., with a registered capital of ¥10 million, aimed at increasing production capacity for food and pharmaceutical packaging equipment[97]. - The company has committed to improving its governance structure and attracting professional talent to enhance sustainable development capabilities[131]. Innovation and R&D - The company established a research and innovation mechanism focusing on customer and market needs, resulting in 37 authorized patents, including 10 invention patents[44]. - The company has received several awards for its innovative packaging technologies, enhancing its market reputation and brand influence[61]. - The company has developed new products such as a low-cost cheese filling machine and a fully automated packaging line, expected to enhance market competitiveness[109]. - The company is collaborating with Dalian University of Technology on key technology research for cheese filling machines, aiming for industrial application[110]. - The company has established partnerships with research institutions and universities to mitigate risks associated with single-mode R&D failures[134]. Market Position and Strategy - The company specializes in high-flexibility intelligent packaging equipment, focusing on the pharmaceutical and food sectors[24]. - The packaging equipment market is projected to grow from 917 billion USD in 2019 to 1.05 trillion USD by 2024, indicating significant market potential[57]. - The company is positioned in a rapidly growing mid-to-high-end pharmaceutical equipment market, with domestic equipment expected to replace imports[127]. - The company’s future strategy includes focusing on technological innovation and expanding into upstream and downstream industries within the packaging equipment sector[130]. Shareholder Commitments and Transactions - The company has committed to measures to compensate for dilution of immediate returns, with actions taken to address this issue since May 2022[161]. - The controlling shareholders committed to not interfere with the company's management or misappropriate company interests, ensuring that their actions align with the company's profit distribution policies[164]. - The company has committed to publicly disclose any failure to fulfill commitments and apologize to shareholders and the public[166]. - The company has outlined specific measures to ensure that related party transactions are necessary for its operational development and do not harm the interests of other shareholders[166]. Tax Benefits and Financial Incentives - The company received a tax benefit of 5.51 million yuan in 2022, accounting for 11.54% of the total profit, highlighting the importance of tax incentives to profitability[14]. - The company has received a tax reduction on corporate income tax from 25% to 15% due to its recognition as a high-tech enterprise[101]. - In 2022, the company enjoyed a tax benefit of 5.5096 million yuan, accounting for 11.54% of total profit, but risks exist if tax policies change after the expiration of high-tech enterprise certification[139].

证券代码：838810 证券简称：春光药装 公告编号：2023-031 辽宁春光制药装备股份有限公司 关于公司为全资子公司申请银行授信提供担保的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、担保情况概述 （一）担保基本情况 辽宁春光制药装备股份有限公司（以下简称"公司"）为支持全资子公司辽 宁典冠科技有限公司（以下简称"典冠科技"）项目建设及资金需求，拟为典冠 科技申请银行授信提供担保，具体情况如下： 单位：万元 案》。议案表决结果：同意 9 票；反对 0 票；弃权 0 票。 本议案尚需提交股东大会审议。 二、被担保人基本情况 被担保人名称：辽宁典冠科技有限公司 是否为控股股东、实际控制人及其关联方：否 | 被担保人 | 贷款银行 | 融资金额 | 担保金额 | 授信年限 | 担保方式 | | --- | --- | --- | --- | --- | --- | | 辽宁典冠科 | 中国建设银 行股份有限 | | | | 连带责任保 | | | | 16,000.00 | 16,000.0 ...

中信建投证券股份有限公司 关于辽宁春光制药装备股份有限公司 对外担保的专项核查意见 中信建投证券股份有限公司（以下简称"中信建投"或"保荐机构"）作为辽宁春 光制药装备股份有限公司（以下简称"春光药装"或"公司"）向不特定对象公开发行 股票的保荐机构，根据《证券发行上市保荐业务管理办法》《北京证券交易所证券发行 上市保荐业务管理细则》《北京证券交易所股票上市规则（试行）》等有关规定，对春 光药装本次对外担保的事项进行了审慎核查，核查情况如下： 一、对外担保概述 二、被担任人基本情况 1、基本情况 | 公司名称 | 辽宁典冠科技有限公司 | | | | | --- | --- | --- | --- | --- | | 注册地址 | 辽宁省锦州市松山新区黄海大街 号 楼 46-5 3 | | | | | 企业类型 | 有限责任公司（非自然人投资或控股的法人独资） | | | | | 成立日期 | 年 月 2022 | 3 | 31 | 日 | | 注册资本 | 万元 1,000 | | | | | 法人代表 | 毕春光 | | | | | 经营范围 | 一般项目：包装专用设备制造，包装专用设备销售，工业机器人制 ...